Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 175: 300-14, 2011 Feb 23.
Article in English | MEDLINE | ID: mdl-21182905

ABSTRACT

The purpose of this study was to determine whether α(1)-adrenoceptors are expressed on primary nociceptive afferents that innervate healthy skin. Skin and dorsal root ganglia were collected from adult male Wistar rats and assessed using fluorescence immunohistochemistry with antibodies directed against α(1)-adrenoceptors alone or in combination with specific labels including myelin basic protein and neurofilament 200 (markers of myelinated nerve fibres), protein gene product 9.5 (a pan-neuronal marker), tyrosine hydroxylase (sympathetic neurons), isolectin B(4) (IB(4): non-peptidergic sensory neurons), calcitonin gene related peptide (CGRP) and transient receptor potential vanilloid receptor 1 (TRPV1) (peptidergic sensory neurons). Double labelling in dorsal root ganglia confirmed the expression of α(1)-adrenoceptors within sub-populations of CGRP, IB(4) and TRPV1 immunoreactive neurons. Myelinated and unmyelinated sensory nerve fibres in the skin expressed α(1)-adrenoceptors whereas sympathetic nerve fibres did not. The expression of α(1)-adrenoceptors on C- and A-delta nociceptive afferent fibres provides a histochemical substrate for direct excitation of these fibres by adrenergic agonists. This may help to explain the mechanism of sensory-sympathetic coupling that sometimes develops on surviving primary nociceptive afferents in neuropathic pain states.


Subject(s)
Ganglia, Spinal/metabolism , Nociceptors/metabolism , Receptors, Adrenergic, alpha-1/biosynthesis , Sensory Receptor Cells/metabolism , Skin/innervation , TRPV Cation Channels/biosynthesis , Afferent Pathways/metabolism , Afferent Pathways/pathology , Animals , Ganglia, Spinal/cytology , Ganglia, Spinal/physiology , Male , Nociceptors/pathology , Nociceptors/physiology , Pain/metabolism , Pain/physiopathology , Rats , Rats, Wistar , Receptors, Adrenergic, alpha-1/physiology , Sensory Receptor Cells/cytology , Sensory Receptor Cells/physiology , Synaptic Transmission/physiology , TRPV Cation Channels/physiology
2.
Neuroscience ; 155(4): 1227-36, 2008 Sep 09.
Article in English | MEDLINE | ID: mdl-18652880

ABSTRACT

Reg-2 is a secreted protein that is expressed de novo in motoneurons, sympathetic neurons, and dorsal root ganglion (DRG) neurons after nerve injury and which can act as a Schwann cell mitogen. We now show that Reg-2 is also upregulated by DRG neurons in inflammation with a very unusual expression pattern. In a rat model of monoarthritis, Reg-2 immunoreactivity was detected in DRG neurons at 1 day, peaked at 3 days (in 11.6% of DRG neurons), and was still present at 10 days (in 5%). Expression was almost exclusively in the population of DRG neurons that expresses the purinoceptor P2X(3) and binding sites for the lectin Griffonia simplicifolia IB4, and which is known to respond to glial cell line-derived neurotrophic factor (GDNF). Immunoreactivity was present in DRG cell bodies and central terminals in the dorsal horn of the spinal cord. In contrast, very little expression was seen in the nerve growth factor (NGF) responsive and substance P expressing population. However intrathecal delivery of GDNF did not induce Reg-2 expression, but leukemia inhibitory factor (LIF) had a dramatic effect, inducing Reg-2 immunoreactivity in 39% of DRG neurons and 62% of P2X(3) cells. Changes in inflammation have previously been observed predominantly in the neuropeptide expressing, NGF responsive, DRG neurons. Our results show that changes also take place in the IB4 population, possibly driven by members of the LIF family of neuropoietic cytokines. In addition, the presence of Reg-2 in central axon terminals implicates Reg-2 as a possible modulator of second order dorsal horn cells.


Subject(s)
Arthritis, Experimental/pathology , Ganglia, Spinal/pathology , Gene Expression/physiology , Lithostathine/metabolism , Neurons/metabolism , Animals , Gene Expression/drug effects , Glial Cell Line-Derived Neurotrophic Factor/metabolism , Indoles , Lectins/metabolism , Leukemia Inhibitory Factor/pharmacology , Male , Proto-Oncogene Proteins c-ret/metabolism , Rats , Rats, Wistar , Receptor, trkA/metabolism , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2X3 , Substance P/metabolism , Time Factors
3.
Rheumatology (Oxford) ; 46(9): 1428-32, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17644821

ABSTRACT

OBJECTIVES: The degradation of tryptophan by indoleamine 2,3-dioxygenase yields a number of immunomodulatory metabolites, including 3-hydroxyanthranilic acid, 3-hydroxykynurenic acid and quinolinic acid. N-(3',4'-dimethoxycinnamonyl) anthranilic acid (3,4-DAA) is a synthetic anthranilic acid derivative that has been used therapeutically in Japan for many years as an anti-allergic drug and has recently been shown to be effective in a murine model of multiple sclerosis. METHODS: In the present study, we tested the efficacy of 3,4-DAA in collagen-induced arthritis, a mouse model of rheumatoid arthritis, and analysed its mechanism of action. RESULTS: Administration of 3,4-DAA after arthritis onset reduced clinical and histological severity of arthritis and reduced pain. It completely abrogated thermal and mechanical hyperalgesia. 3,4-DAA also suppressed Th1 cell activity in lymph node cell cultures and raised serum levels of IL-10. In vitro, 3,4-DAA suppressed IFNgamma production and proliferation of both T and B lymphocytes in a manner comparable with the endogenous tryptophan metabolite, 3-hydroxyanthranilic acid, suggesting similar mechanisms of action. CONCLUSION: It is concluded that 3,4-DAA has both anti-inflammatory and analgesic properties, and may therefore be useful in filling an unmet need, in the treatment of rheumatoid and other forms of arthritis, especially in the light of its analgesic properties.


Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Experimental/drug therapy , ortho-Aminobenzoates/therapeutic use , 3-Hydroxyanthranilic Acid/pharmacology , Animals , Arthritis, Experimental/immunology , Arthritis, Experimental/prevention & control , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/prevention & control , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Hyperalgesia/prevention & control , Lymphocyte Activation/drug effects , Male , Mice , Mice, Inbred DBA , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
4.
Inflamm Res ; 55(6): 236-40, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16955242

ABSTRACT

OBJECTIVE: The inflammatory mediator substance P (SP) acts principally through the neurokinin (NK1) receptor. We assessed the influence of SP on production of NO and its possible role in the pathogenesis of rheumatoid arthritis (RA). METHODS: The effect of SP (0.1-100 nM) on concentrations of the NO metabolite, nitrite, produced by synovial fibroblasts from RA patients was studied. For comparison, the effects of TNF-alpha (0.57 pM-5.7 nM) and IL-1beta (0.57 pM-5.7 nM) were also studied. In parallel studies, footpad inflammation was induced in NK1 receptor knock-out (KO) and wild-type (WT) mice, and swelling and NO metabolite levels were measured. RESULTS: In cultured synoviocytes, SP, TNF-alpha and IL-1beta induced significantly increased nitrite concentrations. Consistent with a role for NO in SP-mediated inflammatory reactions, the plasma NO metabolite level in WT mice was significantly increased at 3 days following an injection of 10 mg/ml Mycobacterium tuberculosis, but there was no significant change in NK1 KO mice. These results were paralleled by the changes in footpad swelling in WT mice compared to NK1 KO mice. CONCLUSION: SP, like TNF-alpha and IL-1beta, induces NO in both rheumatoid synoviocytes and experimental models of inflammation. Treatments directed against SP may have important and hitherto unrecognised anti-inflammatory effects.


Subject(s)
Arthritis, Rheumatoid/metabolism , Neurotransmitter Agents/pharmacology , Nitric Oxide/metabolism , Substance P/physiology , Synovial Membrane/metabolism , Aged , Animals , Arthritis, Rheumatoid/etiology , Arthritis, Rheumatoid/pathology , Cells, Cultured , Disease Models, Animal , Female , Gene Expression Regulation/genetics , Humans , Inflammation/etiology , Inflammation/metabolism , Inflammation/pathology , Interleukin-1beta/pharmacology , Mice , Mice, Knockout , Middle Aged , Nitrates/blood , Nitrites/blood , Receptors, Neurokinin-1/genetics , Receptors, Neurokinin-1/metabolism , Synovial Membrane/pathology , Tumor Necrosis Factor-alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...